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In genome-wide association studies (GWASs) of colorectal cancer, we have identiﬁed two genomic regions in
which pairs of tagging-single nucleotide polymorphisms (tagSNPs) are associated with disease; these com-
prise chromosomes 1q41 (rs6691170, rs6687758) and 12q13.13 (rs7163702, rs11169552). We investigated
these regions further, aiming to determine whether they contain more than one independent association
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Advance Access published on November 10, 2011signal and/or to identify the SNPs most strongly associated with disease. Genotyping of additional sample
sets at the original tagSNPs showed that, for both regions, the two tagSNPs were unlikely to identify a
single haplotype on which the functional variation lay. Conversely, one of the pair of SNPs did not fully cap-
ture the association signal in each region. We therefore undertook more detailed analyses, using imputation,
logistic regression, genealogical analysis using the GENECLUSTER program and haplotype analysis. In the
1q41 region, the SNP rs11118883 emerged as a strong candidate based on all these analyses, sufﬁcient to
account for the signals at both rs6691170 and rs6687758. rs11118883 lies within a region with strong evidence
of transcriptional regulatory activity and has been associated with expression of PDGFRB mRNA. For
12q13.13, a complex situation was found: SNP rs7972465 showed stronger association than either
rs11169552 or rs7136702, and GENECLUSTER found no good evidence for a two-SNP model. However, logis-
tic regression and haplotype analyses supported a two-SNP model, in which a signal at the SNP rs706793 was
added to that at rs11169552. Post-GWAS ﬁne-mapping studies are challenging, but the use of multiple tools
can assist in identifying candidate functional variants in at least some cases.
INTRODUCTION
Using genome-wide association studies (GWASs), we have
identiﬁed14regionsthatcontaintaggingsinglenucleotidepoly-
morphisms (tagSNPs) associated with the risk of colorectal
cancer(CRC)(1).Withinthreeoftheseregions—chromosomes
14q22.2, 15q13.3 and 20p12.3—we have shown that there exist
two SNPs that are independently associated with disease (2). In
two further regions—chromosomes 1q41 and 12q13.13—there
are two SNPs associated with CRC risk, but from the original
GWA analysis, it was unclear as to whether these represented
independent signals of association (1). At 1q41, these SNPs
are rs6691170 (chr1: 220,112,069 bases) and rs6687758 (chr1:
220,231,571); they are in modest pairwise linkage disequilib-
rium (LD) (r
2¼ 0.22; D′ ¼ 0.71). At 12q13.13, the two
SNPs are rs7136702 (chr12: 49,166,483) and rs11169552
(chr12: 49,441,930); these SNPs too are moderately correlated
(r
2¼ 0.11, D′ ¼ 0.76). Our previous analyses had not resolved
the issue of whether there could be more than one independent
CRC SNP in either of these regions (1).
One of the aims of GWASs is the discovery of functional/
causal variants, the effects of which are manifest in the
tagSNP associations. It is, however, very challenging to
proceed from a tagSNP association to identifying functional
variants, and relatively few such studies have been reported to
date. One reason for this is that the correlation matrix
between tagSNP(s) and functional variant(s) at any locus may
be complex. If two association signals occur at tagSNPs at
the same locus, the possible causes include the following:
(i) the associated tagSNPs are in LD;
(ii) there are two independent functional sites, each in LD
with one tagSNP;
(iii) there are two functional sites, but there is true epistasis;
(iv) there is a single functional site on a haplotype deﬁned by
the two tagSNPs;
(v) there are .2 independent functional sites in LD with one
or more tagSNPs;
(vi) there is a mixture of the above possibilities.
It can be extremely hard to distinguish among these possi-
bilities and our inability to de-convolute association signals
may help explain why so much of the heritability of
complex diseases is unexplained by GWASs to date (3).
Despite these problems, functional variant discovery may be
aided by a deeper examination of genetic variation in the
LD blocks in which the tagSNPs reside. Such discovery is
likely to beneﬁt from efforts such as the 1000 Genomes
Project, where a comprehensive discovery of novel variants
has been carried out in several populations.
In this study, we had three aims. First, we wished to inves-
tigate as fully as possible whether there was likely to be one or
more than one functional variant underlying the association
signals at 1q41 and 12q13.13 in CRCs. Secondly, we wanted
to investigate other tagSNPs in these regions for evidence of
further, independent association signals. Thirdly, we wished
to use imputation and functional annotation to reﬁne the
most likely location of the ‘disease-causing’ variant in both
the 1q41 and 12q13.13 regions.
RESULTS
The 1q41 region
We genotyped a total of 48 174 samples (22 832 cases and 25
892 controls) from 17 sample sets at rs6691170 and
rs6687758. This analysis included ﬁve replication case/
control cohorts that were not previously reported (1) for
these SNPs: Kentucky; Prague; EPICOLON; Leiden; and
Australia. After meta-analysis in STATA, both rs6691170
and rs6687758 were, as expected, signiﬁcantly associated
with CRC risk (Table 1), with no evidence of heterogeneity
among studies. Incorporating both SNPs into an unconditional
logistic regression model showed that neither of the pair of
SNPs fully captured the association signal in the region
[odds ratio (OR) ¼ 1.06, P ¼ 1.06 × 10
24 for rs6691170
and OR ¼ 1.07, P ¼ 2.48 × 10
24 for rs6687758]. We used
PLINK to examine the possibility that the two tagSNPs indi-
cated a single high-risk haplotype on which an unknown func-
tional SNP was present (that is, all the functional risk alleles
resided on a haplotype composed solely of one of the four pos-
sible pairs of tagSNP alleles). However, the association signal
was not simply present on the high-risk haplotype TG (for
rs6991170|rs6687758). Instead, the risks for the ‘compound’
(high-low or low-high) haplotypes—GG and TA—were
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Summary Series Ca11 Ca12 Ca22 Co11 Co12 Co22 Ca1 Ca2 Co1 Co2 MAF
ca
MAF
co
OR Ntot Nca Nco
rs6691170; chr1:
220,112,069; z ¼ 6.87;
P ¼ 6.42 × 10
212;
OR ¼ 1.10; 95%
CI ¼ 1.07–1.12;
Phet ¼ 0.39;
I
2 ¼ 5.9%; allele
1 ¼ T; allele 2 ¼ G
UK1/CORGI 130 435 355 100 429 393 695 1145 629 1215 0.38 0.34 1.172 1215 920 922
Scotland1/COGS 134 463 379 130 433 435 731 1221 693 1303 0.37 0.35 1.126 1303 976 998
UK2/NSCCG 398 1395 1058 355 1304 1159 2191 3511 2014 3622 0.38 0.36 1.122 3622 2851 2818
Scotland2/SOCCS 248 941 817 239 967 851 1437 2575 1445 2669 0.36 0.35 1.031 2669 2006 2057
VQ58 277 833 688 359 1234 1096 1387 2209 1952 3426 0.39 0.36 1.102 3426 1798 2689
CFR 149 581 447 155 436 399 879 1475 746 1234 0.37 0.38 0.986 1234 1177 990
UK3/NSCCG 406 1448 1137 367 1251 1198 2260 3722 1985 3647 0.38 0.35 1.116 3647 2991 2816
Scotland3/SOCCS 103 376 326 117 447 363 582 1028 681 1173 0.36 0.37 0.975 1173 805 927
UK4/CORGI2BCD 70 212 213 129 473 445 352 638 731 1363 0.36 0.35 1.029 1363 495 1047
Cambridge 324 1068 805 280 1013 890 1716 2678 1573 2793 0.39 0.36 1.138 2793 2197 2183
COIN/NBS 300 1054 797 326 1170 1005 1654 2648 1822 3180 0.38 0.36 1.090 3180 2151 2501
Helsinki 143 435 351 105 372 340 721 1137 582 1052 0.39 0.36 1.146 1052 929 817
Prague 147 424 363 82 317 252 718 1150 481 821 0.38 0.37 1.066 821 934 651
Kentucky 156 466 388 244 709 630 778 1242 1197 1969 0.39 0.38 1.030 1969 1010 1583
EPICOLON 193 613 520 184 632 578 999 1653 1000 1788 0.38 0.36 1.081 1788 1326 1394
Australia 64 223 129 58 212 168 351 481 328 548 0.42 0.37 1.219 548 416 438
Leiden 141 404 310 92 291 304 686 1024 475 899 0.40 0.35 1.268 899 855 687
rs6687758; chr1:
220,231,571; z ¼ 5.64;
P ¼ 1.70 × 10
28;
OR ¼ 1.09; 95%
CI ¼ 1.06–1.13;
Phet ¼ 0.28;
I
2 ¼ 14.8%; allele
1 ¼ G; allele 2 ¼ A
UK1/CORGI 37 312 568 32 299 598 386 1448 363 1495 0.21 0.20 1.098 1495 917 929
Scotland1/COGS 63 308 606 34 325 642 434 1520 393 1609 0.22 0.20 1.169 1609 977 1001
UK2/NSCCG 121 985 1746 98 898 1822 1227 4477 1094 4542 0.22 0.19 1.138 4542 2852 2818
Scotland2/SOCCS 77 694 1235 74 639 1344 848 3164 787 3327 0.21 0.19 1.133 3327 2006 2057
VQ58 86 605 1106 113 832 1742 777 2817 1058 4316 0.22 0.20 1.125 4316 1797 2687
CFR 50 364 756 51 327 607 464 1876 429 1541 0.20 0.22 0.888 1541 1170 985
UK3/NSCCG 122 947 1920 115 850 1861 1191 4787 1080 4572 0.20 0.19 1.053 4572 2989 2826
Scotland3/SOCCS 48 263 519 51 315 566 359 1301 417 1447 0.22 0.22 0.958 1447 830 932
UK4/CORGI2BCD 24 158 306 45 309 669 206 770 399 1647 0.21 0.20 1.104 1647 488 1023
Cambridge 89 755 1366 76 664 1444 933 3487 816 3552 0.21 0.19 1.165 3552 2210 2184
COIN/NBS 102 701 1330 89 770 1642 905 3361 948 4054 0.21 0.19 1.151 4054 2133 2501
Helsinki 67 385 476 49 317 437 519 1337 415 1191 0.28 0.26 1.114 1191 928 803
Prague 47 335 552 33 230 388 429 1439 296 1006 0.23 0.23 1.013 1006 934 651
Kentucky 41 312 657 57 509 1017 394 1626 623 2543 0.20 0.20 0.989 2543 1010 1583
EPICOLON 57 429 840 46 442 906 543 2109 534 2254 0.20 0.19 1.087 2254 1326 1394
Australia 25 151 264 17 152 269 201 679 186 690 0.23 0.21 1.098 690 440 438
Leiden 45 284 521 28 212 448 374 1326 268 1108 0.22 0.19 1.166 1108 850 688
rs7136702; chr12:
49,166,483; z ¼ 6.69;
P ¼ 2.23 × 10
211;
OR ¼ 1.10; 95%
CI ¼ 1.07–1.12;
Phet ¼ 0.51;
I
2 ¼ 0.0%; allele
1 ¼ T; allele 2 ¼ C
UK1/CORGI 131 433 357 113 430 386 695 1147 656 1202 0.38 0.35 1.110 1202 921 929
Scotland1/COGS 146 443 388 126 444 431 735 1219 696 1306 0.38 0.35 1.131 1306 977 1001
UK2/NSCCG 380 1331 1140 329 1306 1183 2091 3611 1964 3672 0.37 0.35 1.083 3672 2851 2818
Scotland2/SOCCS 276 975 755 275 935 847 1527 2485 1485 2629 0.38 0.36 1.088 2629 2006 2057
VQ58 237 869 694 295 1290 1102 1343 2257 1880 3494 0.37 0.35 1.106 3494 1800 2687
CFR 155 604 427 103 444 450 914 1458 650 1344 0.39 0.33 1.296 1344 1186 997
UK3/NSCCG 402 1388 1190 359 1283 1180 2192 3768 2001 3643 0.37 0.35 1.059 3643 2980 2822
Scotland3/SOCCS 118 310 270 122 401 356 546 850 645 1113 0.39 0.37 1.108 1113 698 879
UK4/CORGI2BCD 81 215 190 151 466 444 377 595 768 1354 0.39 0.36 1.117 1354 486 1061
Cambridge 332 955 903 261 1015 906 1619 2761 1537 2827 0.37 0.35 1.079 2827 2190 2182
COIN/NBS 287 893 844 321 1121 1059 1467 2581 1763 3239 0.36 0.35 1.044 3239 2024 2501
Helsinki 103 389 436 72 334 414 595 1261 478 1162 0.32 0.29 1.147 1162 928 820
Prague 85 419 430 57 291 303 589 1279 405 897 0.32 0.31 1.020 897 934 651
Kentucky 140 478 392 215 750 618 758 1262 1180 1986 0.38 0.37 1.011 1986 1010 1583
EPICOLON 198 642 486 187 623 584 1038 1614 997 1791 0.39 0.36 1.155 1791 1326 1394
Leiden 115 388 341 92 269 321 618 1070 453 911 0.37 0.33 1.162 911 844 682
rs11169552; chr12:
49,441,930; z ¼ 6.88;
P ¼ 5.99 × 10
212;
OR ¼ 0.90; 95%
CI ¼ 0.88–0.93;
Phet ¼ 0.50;
I
2 ¼ 0.0%; allele
1 ¼ T; allele 2 ¼ C
UK1/CORGI 56 328 537 67 350 512 440 1402 484 1374 0.24 0.26 0.891 1374 921 929
Scotland1/COGS 60 369 544 76 406 519 489 1457 558 1444 0.25 0.28 0.869 1444 973 1001
UK2/NSCCG 209 1062 1580 199 1124 1494 1480 4222 1522 4112 0.26 0.27 0.947 4112 2851 2817
Scotland2/SOCCS 111 808 1087 152 821 1084 1030 2982 1125 2989 0.26 0.27 0.918 2989 2006 2057
VQ58 109 665 1026 201 1046 1442 883 2717 1448 3930 0.25 0.27 0.882 3930 1800 2689
CFR 72 450 663 73 408 516 594 1776 554 1440 0.25 0.28 0.869 1440 1185 997
UK3/NSCCG 167 1179 1625 214 1142 1463 1513 4429 1570 4068 0.25 0.28 0.885 4068 2971 2819
Scotland3/SOCCS 14 127 176 80 321 490 155 479 481 1301 0.24 0.27 0.875 1301 317 891
UK4/CORGI2BCD 34 175 277 80 395 554 243 729 555 1503 0.25 0.27 0.903 1503 486 1029
Cambridge 155 824 1241 163 853 1172 1134 3306 1179 3197 0.26 0.27 0.930 3197 2220 2188
COIN/NBS 135 818 1107 189 973 1338 1088 3032 1351 3649 0.26 0.27 0.969 3649 2060 2500
Helsinki 103 407 401 153 356 303 613 1209 662 962 0.34 0.41 0.737 962 911 812
Prague 51 375 508 38 273 340 477 1391 349 953 0.26 0.27 0.936 953 934 651
Kentucky 58 377 575 93 665 825 493 1527 851 2315 0.24 0.27 0.878 2315 1010 1583
EPICOLON 56 453 817 75 471 848 565 2087 621 2167 0.21 0.22 0.945 2167 1326 1394
Leiden 53 304 492 57 251 378 410 1288 365 1007 0.24 0.27 0.878 1007 849 686
Ca, cases; Co, controls; 11, rare homozygote; 12, heterozygote; 22, common homozygote; 1, minor allele; 2, major allele. Allele 1 is risk allele for rs6691170, rs6687758 and
rs7136702; allele 2 is risk allele for rs11169552. MAF, minor allele frequency; OR, odds ratio.
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ent with a functional SNP being in complete LD with a haplo-
type indicated by the pair of tagSNPs (Supplementary
Material, Table S1). We also tested for evidence of epistasis
between rs6691170 and rs6687758 using case–control logistic
regression analysis, incorporating interaction between SNPs as
a variable, but no evidence of deviation from log-additive SNP
effects was found (P ¼ 0.292).
Having failed to ﬁnd evidence for the simplest situations—
namely that one of each tagSNP pair captured the great major-
ity of the association signal or that the tagSNPs essentially
acted as simple two-locus tags for the functional variants in
each region—we attempted to deconvolute the 1q41 signal
by association testing of imputed SNPs in the region. The
three GWAS sample sets, UK1, Scotland 1 and VQ58, were
imputed to the combined 1000 genomes and HapMap3 refer-
ence set. A total of 630 SNPs in the 220–221 Mb region on
chromosome 1q41 was successfully imputed from 76 geno-
typed SNPs. The strongest association signal (Fig. 1, Supple-
mentary Material, Table S2), as measured by association test
P-value, was at rs11118883 (chr1: 220,127,645), an imputed
SNP in moderate LD with rs6691170 (r
2¼ 0.40, D′ ¼ 0.74)
and rs6687758 (r
2¼ 0.31, D′ ¼ 0.77).
We then used reverse stepwise logistic regression analysis
to determine whether rs6691170 and rs6687758, or other com-
binations of SNPs, best accounted for the association between
CRC and 1q41 variation. Using a ﬁnal signiﬁcance threshold
of P ¼ 0.01, we found that two imputed SNPs, rs11118883
and rs12726661, were most strongly associated with the
CRC risk (Table 2, Supplementary Material, Table S2). By
comparison, a joint analysis of rs6687758 and rs6691170 in
the same three GWAS data sets gave much weaker evidence
of association, as assessed using the Akaike Information Cri-
terion (AIC). Indeed, a model incorporating rs11118883
alone—although not one with rs12726661 alone—provided a
better ﬁt than a model incorporating both rs6687758 and
rs6691170; haplotype-based association analysis supported
these ﬁndings (data not shown).
We were surprised to note that in a single-SNP analysis the
direction of effect for rs12726661 was reversed—the minor
Figure 1. Individual SNP associations in the 1q41 region. Association testing was performed in SNPtest using typed and imputed genotypes from the three
GWAS series (UK1, Scotland1 and VQ58) and displayed using SNAP (http://www.broadinstitute.org/mpg/snap/). The X-axis shows position on chromosome
1 and the Y-axis, 2log10(P) from the per allele association test. The most strongly associated SNP, rs11118883, is shown as a large diamond, and the colours of
other data points reﬂect the LD between that SNP and rs11118883. The smaller diamond points indicate genotyped SNPs and the triangles indicate imputed
SNPs. The blue line represents recombination rates.
Table 2. Two-SNP logistic regression analysis showing best signal in the 1q41 region in comparison with the originally reported SNPs
SNPs Positions (bases) LD (r
2, D′) Risk allele (freqcases, freqcontrols) No. cases, no. controls OR 95% CI ZP -value AIC
rs6691170 220,112,069 0.15, T (0.38,0.36) 3272, 1.09 1.01–1.17 2.95 0.0032 10486
rs6687758 220,231,571 0.65 G (0.22,0.20) 4572 1.08 0.98–1.18 1.61 0.108
rs11118883 220,127,645 0.92, A (0.32,0.29) 3206, 2.32 1.49–3.62 3.71 2.07 × 10
24 10475
rs12726661 220,134,411 1.00 A (0.68,0.71) 4452 0.49 0.32–0.76 3.16 1.58 × 10
23
LD is shown for the pair of SNPs being tested. OR, odds ratio; AIC, Akaike information criterion (AIC ¼ 22 ∗ log-likelihood + 2 ∗ (numberof parameters)).Note
the lower AIC, showing a better model ﬁt, for the test of rs11118883 + rs12726661 compared with rs6691170 + rs6687758. Individual AICs for these four SNPs
were, respectively, 10487, 10489, 10484 and 10487.
Human Molecular Genetics, 2012, Vol. 21, No. 4 937allele was associated with disease risk—compared with that in
the two-SNP analysis. We determined that rs11118883 and
rs12726661 were in strong LD (r
2¼ 0.98, D′ ¼ 1.00) in our
samples, consistent with data from the 1000 genomes project
and HapMap3 that had been used for imputation. Examination
of the genotype distribution in our data set showed that devi-
ation from perfect LD between the SNPs resulted from two
sets of individuals: (i) 50 homozygous for the major allele at
rs12726661 and heterozygous at rs11118883; and (ii) 15 het-
erozygous at rs12726661 and homozygous for the minor
allele at rs11118883. Speciﬁcally, 28/50 in category (i) were
cases and 4/11 in category (ii) were cases. For these 65 indi-
viduals, the risk of CRC was signiﬁcantly greater than that
of individuals with the other genotypes at rs12726661 and
rs11118883 (OR ¼ 2.10, P ¼ 0.003, x
2
1 test). A potential
explanation for our apparently paradoxical ﬁndings is that
there exists another allele, almost certainly relatively
rare, that is associated with the minor allele of rs12726661
(but not with rs11118883), and that is protective against the
CRC risk.
We then analysed our UK1, Scotland 1 and VQ58 indivi-
duals using GENECLUSTER with the original GWAS SNP
genotypes in the rs6691170/6687758 region as inputs. There
was no evidence to favour an underlying two-locus model
over a one-SNP model (Fig. 2). The predicted most strongly
associated single SNP was rs11577023, a SNP that is in
very strong LD with rs11118883 (r
2¼ 0.93, D′ ¼ 1.0) in
our data.
We genotyped rs11118883 directly in a set of 84 UK control
samplesandfoundcompleteconcordancewiththeimputedgen-
otypes. rs11118883 (chr1:220,127,645) lies in a gene desert,
within a region of LD that extends approximately from 220.0
to 220.3 Mb. The nearest gene,  150 kb towards the centro-
mere, is the MAP kinase regulator dual-speciﬁcity phosphatase
10 (DUSP10). DUSP10 inactivates p38 and also the Jun
N-terminal kinase that phosphorylates c-Jun which is believed
to play a role in CRC pathogenesis. rs11118883 itself lies
upstream of DUSP10 within a region with strong evidence of
transcriptional regulatory activity (http://genome.ucsc.edu).
Using 1000 genomes data, we found that rs11118883 is in
strong LD (r
2. 0.7) with at least six SNPs (rs12738322,
rs12726661, rs4129271, rs11577023, rs10746414 and
rs12137702). Of these, rs10746414 and rs12137702 are also
close to regions with potential effects on transcription.
The 12q13.13 region
Analysis of the 12q13.13 region proceeded in parallel with
that of the 1q41 region using essentially the same strategy.
We initially conﬁrmed the individual associations of SNPs
rs7136702 and rs11169552 with the CRC risk in the extended
data sets (Table 1). Unconditional logistic regression analysis
did not exclude the possibility that the two SNPs had
independent effects; for rs7136702 and rs11169552, the
association statistics were P ¼ 1.63 × 10
25 (OR ¼ 1.07) and
P ¼ 1.70 × 10
27 (OR ¼ 0.92), respectively, showing that
one SNP did not simply capture all of the association
signals. Further analysis showed that the association signal
was not derived from a single high-risk haplotype tagged
by rs7136702 and rs11169552 (Supplementary Material,
Table S3) and there was no evidence of epistasis between
the SNPs (P ¼ 0.903).
We imputed SNPs within the 48.5–50 Mb region of
chromosome 12 using the combined 1000 genomes and
HapMap3 reference panel in the 3 GWAS sample sets
(UK1, Scotland 1 and VQ58) (Fig. 3, Supplementary Material,
Table S4). A total of 2736 SNPs was successfully imputed
from 158 genotyped SNPs. The most signiﬁcant single-SNP
association was at the imputed SNP rs7972465 [OR ¼ 1.18,
95% conﬁdence interval (CI) 1.11–1.27, P ¼ 8.22 × 10
27),
a signal slightly stronger than that of rs11169552 (OR ¼
0.85, 95% CI 0.79–0.91, P ¼ 1.08 × 10
25) and notably stron-
ger than that of rs7136702 (OR ¼ 1.13, 95% CI 2.06–1.21,
P ¼ 3.85 × 10
24). Direct genotyping in 91 UK control indivi-
duals showed that imputation of rs7972465 was very good,
although not perfect (r
2¼ 0.93).
Reverse stepwise logistic regression analysis was then used
to assess whether rs11169552 and rs7136702, or other combi-
nations of SNPs in the region, best accounted for the associ-
ation between CRC and 12q13.13 variation (Table 3). Many
highly correlated SNPs exist within the region, making this
analysis difﬁcult. Nonetheless, while rs11169552 remained
in the regression model after stepwise elimination of less
strongly associated SNPs, a number of SNPs provided
improved or similar associations compared with rs7136702
in a two-SNP model with rs11169552. One of these SNPs
was rs7972465 (Table 3, Fig. 4), but another SNP, rs706793,
a SNP in very low LD with rs11169552 (Table 3), provided
a larger improvement in the AIC (see also Supplementary
Material, Table S4).
We then undertook GENECLUSTER analysis of the UK1,
Scotland 1 and VQ58 sample sets in the 12q13.13 region.
There was no good evidence to distinguish between under-
lying two-locus and one-locus models (Fig. 5), although the
association signal showed two peaks at  48.85 Mb (close to
rs706793) and at  49.45 Mb (very close to rs11169552)
that could not readily be explained by long-range LD
between these two regions (Supplementary Material,
Fig. S1). The predicted most strongly associated SNP under
the one-SNP model was rs3184122 (Supplementary Material,
Table S4), a variant that is in moderate or strong LD
(Fig. 5) with rs11169552 (r
2¼ 0.19, D′ ¼ 0.92), rs7136702
(r
2¼ 0.49, D′ ¼ 0.73) and rs706793 (r
2¼ 0.47, D′ ¼ 0.94),
and strong LD with rs7972465 (r
2¼ 0.87, D′ ¼ 1.00).
Since the various analyses had not resolved the question of
whether there exist one or two independent CRC-associated
SNPs in the 12q13.13 region, we used PLINK to examine
the associations with disease of the haplotypes (Fig. 4)f o r
rs706793, rs7972465 and rs11169552. As expected, the haplo-
type CGC was most strongly associated with risk (Table 4,
Supplementary Material, Table S5). The G (risk) allele at
rs7972465 was essentially present only on this haplotype,
but it appeared that haplotypes containing the T allele at
rs7972465 were not all low risk and therefore that
rs7972465 did not explain all the association signal. We there-
fore considered the association signals when we ﬁxed the
alleles at rs706793 and rs11169552 and allowed those at
rs7972465 to vary, and vice versa. Initially, we undertook
simple comparisons between haplotype frequencies in cases
and controls, and found that the rs706793 and rs11169552
938 Human Molecular Genetics, 2012, Vol. 21, No. 4Figure 2. GENECLUSTER output for the 1q41 region. The upper left panel compares the Bayes factors (BFs) for models in which the association signals at
rs6691170 and 6687758 are derived from either one functional SNP (red) or two functional SNPs (green). Recombination rates are also shown as a red line. The
upper right panel shows the log10(BF) at the focal position—the site of the highest log10(BF), here chr1:220,129,000 bases—under one- and two-SNP models.
The lower right panel shows reconstructed genealogies for UK1, Scotland1 and VQ58 combined, based on each individual’s genotypes in the region from the
Illumina Hap300/370/550 panels and HapMap2 data. The most likely positions of SNP origins under the one-SNP model (blue, rs11577023) and two-SNP model
(green and red) are shown. These result in counts of cases and controls and relative risks as indicated in the upper right panel. The lower left panel shows hap-
lotypes (rows) and SNPs (columns). Note that the region analysed extends for several Mb ﬂanking rs6691170 and 6687758; although no signal reaches nominal
signiﬁcance at log10(BF) ¼ 4, there is some evidence of a second independent region of 1q associated with CRC at  218.2 Mb, as we have reported previously.
The importance of rs11577023 was supported by the Margarita analysis in which it was the second most strongly associated with disease (P ¼ 3.59 × 10
24).
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signiﬁcantly higher frequencies in cases than controls (Supple-
mentary Material, Table S6). Since this analysis suggested that
there might be independent effects of rs706793 and
rs11169552—and that the signal at rs7972465 resulted from
LD with these two SNPs—we proceeded to a further evalu-
ation of this possibility using conditional haplotype analysis
in PLINK. We again compared two scenarios, (i) in which
the CGC and CTC haplotypes were equivalent (that is,
varying rs7972465) and (ii) in which the CTC and TTT hap-
lotypes were equivalent (that is, varying rs706793 and
rs11169552). No effect was seen in the ﬁrst case (likelihood
ratio test, P ¼ 0.35), whereas there was a signiﬁcant difference
in the second case (P ¼ 0.023), again supporting effects of
rs706793 and rs11169552 rather than rs7972465.
Furthergenotypinginadditionalsamplesetsstrengthenedthe
rs706793associationwithCRC,althoughitdidnotreachformal
signiﬁcance and there was some evidence of inter-study hetero-
geneity, the origins of which remain unclear (Supplementary
Material,TableS7).Logisticregressionanalysisintheextended
samplesetcontinuedtosupportamodelincorporatingrs706793
and rs11169552 (P ¼ 8.38 × 10
24 and P ¼ 7.82 × 10
26,
respectively, AIC ¼ 27932) over one with rs7163702
and rs11169552 (P ¼ 3.05 × 10
25 and P ¼ 9.05 × 10
23,
AIC ¼ 27999).
rs706793 (chr12:48,754,036) and rs11169552
(chr12:49,441,930) are separated by a predicted recombination
hotspot at  48.8 Mb in the HapMap data (Fig. 3) but not in
our own data (Fig. 5), although LD in the region is complex
(Supplementary Material, Fig. S1). The 12q13.13 region
Figure 3. Individual SNP associations in the 12q13.13 region. Legend is as for Figure 1.
Table 3. Two-SNP logistic regression analysis showing best signals in the 12q13.13 region in comparison with the original reported SNPs
SNPs Genotyped or
imputed?
Positions
(bases)
LD (r
2, D′) Risk allele (freqcases, freqcontrols) No, cases,
no. controls
OR 95% CI zP -value AIC
rs11169552 Genotyped 49,441,930 0.040 C (0.76, 0.73) 3276 0.92 0.81–0.94 3.37 7.52 × 10
24 10473
rs7136702 Genotyped 49,166,483 0.57 T (0.37, 0.35) 4576 1.08 1.01–1.16 2.13 0.033
rs11169552 Genotyped 49,441,930 0.19 C (0.76,0.73) 3206 0.89 0.82–0.97 2.69 0.007 10469
rs3184122 Imputed 48,856,394 0.92 C (0.41,0.37) 4480 1.12 1.04–1.21 2.96 0.003
rs11169552 Genotyped 49,441,930 0.06 C (0.76, 0.73) 3268 0.88 0.81–0.95 3.40 6.74 × 10
24 10468
rs35031884 Imputed 49,063,840 1.00 A (0.32,0.29) 4554 1.15 1.05–1.25 3.19 0.0014
rs11169552 Genotyped 49,441,930 0.17 C (0.76,0.73) 3268 0.90 0.83–0.97 2.64 0.008 10466
rs7972465 Imputed 48,832,392 0.89 G (0.21,0.18) 4563 1.14 1.06–1.22 3.43 6.04 × 10
24
rs11169552 Genotyped 49,441,930 0.002 C (0.76,0.73) 3266 0.84 0.78–0.91 4.56 5.12 × 10
26 10426
rs706793 Genotyped 48,754,036 0.095 C (0.60,0.57) 4557 0.49 0.32–0.76 3.23 0.0012
SNP pairs are shownin order of descendingAikake Information Criterion(AIC). Note that in single-SNPanalysis, rs706793 provided only slightly worse evidence
of association (OR ¼ 0.90, 95% CI 0.84–0.96, P ¼ 0.002) than in combined analysis with rs11169552. Individual AICs for rs11169552, rs7136702, rs3184122,
rs35031884, rs7972465 and rs706793 were, respectively, 10476, 10483, 10475, 10477, 10471 and 10447. Incorporation of rs7972465 into a regression model with
rs11169552 and rs706793 did not improve the model’s ﬁt (AIC ¼ 10426).
940 Human Molecular Genetics, 2012, Vol. 21, No. 4contains coding genes ACCN2, SMARCD1, GPD1, LASS5,
LIMA1 and ATF1. ACCN2 probably encodes an ion channel
protein, SMARCD1 is part of chromatin remodelling
complex SNF/SWI, GPD1 is glycerol-3-phosphate dehydro-
genase and LASS5 is probably a ceramide synthase. LIMA1
codes for EPLIN, a protein downregulated in some cancers.
ATF1 is a transcription factor centrally involved in the stress
response and in the pathogenesis of angiomatoid ﬁbrous his-
tiocytoma and clear cell sarcoma through translocation. Sup-
plementary Material, Table S8 lists SNPs in strong LD (r
2.
0.70) with rs706793, rs7972465 or rs11169552, and provides
annotation for those with evidence of potential roles in gene
or protein regulation or function.
DISCUSSION
We have undertaken additional genotyping and more detailed
analysis in order to understand better the dual tagSNP associ-
ation signals that we observed on chromosomes 1q41
(rs6991170, rs6687758) and 12q13.13 (rs11169552,
rs7136702) in a GWAS of CRC (1). In both cases, genotyping
of additional sample series conﬁrmed the originally reported
associations, without demonstrating good evidence for the
three simplest scenarios: independent functional variants;
capture of the association signal by one of the pair of SNPs;
or two-SNP tagging of a single haplotype on which functional
variation lay. We therefore proceeded to more detailed ana-
lyses in each region, after imputation of genotypes where
appropriate in the data sets with best coverage of each
region (UK1, Scotland1 and VQ58). It is conceivable that
the analysis of these three data sets, which had already been
used in SNP discovery, would introduce a small amount of
bias into the ﬁne mapping. However, we reasoned that the
marginal differences in association that might occur would
be more than outweighed by the power provided by the use
of these data sets.
For 1q41, the single-SNP association test, logistic regres-
sion analysis and GENECLUSTER all found that SNP
rs11118883, or a SNP in strong LD, was most likely to be
responsible for the signal of association. This SNP itself is a
very good functional candidate, lying within or immediately
adjacent to regions bearing histone methylation and
acetylation marks, DNAse I hypersensitive sites and sites of
transcription factor binding (http://genome.ucsc.edu/cgi-bin/
hgTrackUi?hgsid=195445293&c=chr1&g=wgEncodeReg).
The SCAN expression Quantitative Trait Locus (eQTL) data-
base (4) reports rs11118883 being associated (P ¼ 8 × 10
25)
in Europeans with expression of platelet-derived growth
factor b (PDGFRB, chr5q31–q32), although this association
requires conﬁrmation in appropriate cell types for the CRC
risk and is not present in the Genevar eQTL database
(http://www.sanger.ac.uk/resources/software/genevar) (5).
The possibility that the minor allele of rs12726661 is asso-
ciated with a second, presumably rare, variant that is protect-
ive against the CRC risk is intriguing. While speculative, such
a scenario has precedents, such as the MDM2 promoter SNP
rs117039649 (6).
For 12q13.13, a complex situation was found. Single-SNP
analysis found variants with much stronger association
signals than either rs11169552 or rs7136702, notably at
rs7972465 although small imputation inaccuracies may have
inﬂated this signal. GENECLUSTER analysis found no
greater evidence for a two-SNP than one-SNP model and
detected the best signal for the former at a SNP, rs3184122,
that is in strong LD with rs7972465. Logistic regression
analysis, however, supported a two-SNP model, in which
a signal at rs706793 was added to that at
rs11169552. rs706793 and rs11169552 are in very weak LD,
but rs706793 is in moderate LD with rs7163702 (r
2¼ 0.20,
D′ ¼ 0.60). Haplotype analysis supported the logistic regres-
sion analysis, in that the genotype at rs7972465 did not
affect the risk associated with the rs706793–rs11169552 hap-
lotypes, whereas the reverse scenario (high- versus low-risk
rs706793–rs11169552 haplotypes) did affect risk. As
regards eQTLs for the 12q13.13 SNPs, Genevar
shows rs706793 to be associated with LASS5 expression
(at P , 10
24), although this association is not reported in
SCAN.
Figure 4. LD and main haplotypes at SNPs with best evidence of association on 12q13.13. Note that in this Haploview output from HapMap3 data, the alleles at
rs706793 are shown on the opposite strand (that is G/A rather than C/T as used in the rest of this manuscript).
Human Molecular Genetics, 2012, Vol. 21, No. 4 941Clearly, all post-GWAS ﬁne-mapping studies face intrinsic
difﬁculties, such as the use of imputed genotypes, despite the
use of stringent criteria for SNP inclusion, and a limited ability
to differentiate among association signals of similar magni-
tudes. The analysis of the 12q13.13 region illustrates some
of these problems well. Although a much more strongly
Figure 5. GENECLUSTER output for the 12q13.13 region. The legend is as for Figure 2, except that the focal position is Chr12:48,849,000 and the double peak
of association at  48.85 and 49.45 Mb should be noted. The top SNP (blue dot) under the one-SNP model is the imputed SNP rs3184122. The top-genotyped
SNP in the GENECLUSTER analysis was rs7138945, which was the SNP with the second-best association signal in Margarita (P ¼ 1.14 × 10
25).
942 Human Molecular Genetics, 2012, Vol. 21, No. 4CRC-associated SNP than the original tagSNPs was identiﬁed
through imputation, the balance of evidence slightly favours
this signal resulting from two independent association
signals, as we have previously found for the GREM1 locus
(2). In the 1q41 region, in contrast, rs11118883—a SNP in
moderate LD with both the original tagSNPs—emerged as
an excellent candidate for the functional variant.
MATERIALS AND METHODS
Sample sets
The Kentucky samples comprised 1020 incident colon
cancer cases and 1598 population controls of white Euro-
pean origin recruited between July 2003 and December
2009. Eligible cases were identiﬁed through the population-
based Surveillance, Epidemiology and End Results (SEER)
Kentucky Cancer Registry covering all residents living in
the State of Kentucky at the time of diagnosis. We used
random digital dialling to recruit population controls who
were 40 years of age or older and had no personal history
of cancer other than skin cancer. We excluded those with
known inﬂammatory bowel diseases, family history of
familial adenomatous polyposis and hereditary non-
polyposis CRC.
The Prague cases (7) were patients with histologically con-
ﬁrmed CRC recruited between September 2004 and February
2009 from nine oncology departments in the Czech Republic:
Prague (two), Benesov, Brno, Liberec, Ples, Pribram, Usti nad
Labem and Zlin. During this period, a total of 1554 cases pro-
vided blood samples. This study includes 1001 subjects who
could be interviewed, provided biological samples and were
genotyped. Controls were 683 hospital-based volunteers with
negative colonoscopy results for malignancy or idiopathic
bowel diseases (CFCC, cancer-free colonoscopy inspected
controls). CFCCs were selected from among individuals
admitted to the same hospitals during the same period of the
recruitment of the cases. The reasons for undergoing the
colonoscopy were: (i) positive faecal occult blood test, (ii)
haemorrhoids, (iii) abdominal pain of unknown origin, or
(iv) macroscopic bleeding.
Details of other sample sets have been reported previously
(2) and are provided brieﬂy below.
UK1 (CORGI) comprised 922 cases with colorectal neopla-
sia (47% male) ascertained through the Colorectal Tumour
Gene Identiﬁcation (CORGI) consortium. All had at least
one ﬁrst-degree relative affected by CRC and one or more
of the following phenotypes: CRC at age 75 or less; any colo-
rectal adenoma (CRAd) at age 45 or less; ≥3 CRAds at age 75
or less; or a large (.1 cm diameter) or aggressive (villous
and/or severely dysplastic) adenoma at age 75 or less. The
929 controls (45% males, 55% females) were spouses or part-
ners unaffected by cancer and without a personal family
history (to second degree relative level) of colorectal neopla-
sia. Known dominant polyposis syndromes, HNPCC/Lynch
syndrome or bi-allelic MUTYH mutation carriers were
excluded.
Scotland1 (COGS) included 980 CRC cases (51% male;
mean age at diagnosis 49.6 years, SD+6.1) and 1002 cancer-
free population controls (51% male; mean age 51.0 years;
SD+5.9). Cases were for early age at onset (age ≤ 55
years). Known dominant polyposis syndromes, HNPCC/
Lynch syndrome or bi-allelic MUTYH mutation carriers were
excluded. Control subjects were sampled from the Scottish
population NHS registers, matched by age (+5 years),
gender and area of residence within Scotland.
VQ58 comprised 1832 CRC cases (1099 males, mean age of
diagnosis 62.5 years; SD+10.9) from the VICTOR and
QUASAR2 (www.octo-oxford.org.uk/alltrials/trials/q2.html)
clinical trials of adjuvant therapy in stage II/III CRC. There
were 2720 population control genotypes (1391 males) from
the Wellcome Trust Case-Control Consortium 2 (WTCCC2)
1958 birth cohort (also known as the National Child Develop-
ment Study), which included all births in England, Wales and
Scotland during a single week in 1958.
The Australian study comprised 591 patients treated for
CRC at the Royal Melbourne, Western and St Francis
Xavier Cabrini Hospitals in Melbourne from 1999 to 2009.
The 2353 controls were derived from Queensland or
Melbourne: for the former, the controls came from the
Brisbane Twin Nevus Study; for the latter, individuals were
participants in the Genes in Myopia study. There was no
overlap between the CFR and Australian data sets. Owing to
potential residual ethnic heterogeneity within the Melbourne
population, for the Australian cohort only we performed an
additional screen to minimize heterogeneity after performing
principal components analysis (PCA) to remove individuals
who clustered with non-CEU individuals (see below). We
achieved this by performing PCA on the Australian cases
and controls without reference samples of known ancestry.
We then paired each case with a control in a 1:1 ratio based
on a maximum separation of 0.050 using the ﬁrst and
second eigenvectors. All unpaired samples were excluded,
leaving 441 cases and 441 controls in the study. Calculation
of the genomic inﬂation factor, lGC, showed this to be 1.02
after this ﬁltering.
UK2 (NSCCG) consisted of 2854 CRC cases (58% male,
mean age at diagnosis 59.3 years; SD+ 8.7) ascertained
through two ongoing initiatives at the Institute of Cancer
Research/Royal Marsden Hospital NHS Trust (RMHNHST)
from 1999 onwards—The National Study of Colorectal
Cancer Genetics (NSCCG) and the Royal Marsden Hospital
Trust/Institute of Cancer Research Family History and DNA
Table 4. Haplotype analysis in the 12q13.13 region
Haplotype Freq. in cases Freq. in controls OR P-value
TTT 0.0922 0.1085 0.82 5.3 × 10
24
CTT 0.1407 0.1567 0.87 4.5 × 10
23
CGC 0.3829 0.3443 1.19 6.2 × 10
27
TTC 0.3102 0.3194 0.96 0.212
CTC 0.0739 0.0710 1.05 0.483
Haplotypes (cen-tel) at rs706793, rs7972465 and rs11169552 were analysed,
notwithstanding the low LD between the ﬁrst and last of these SNPs. Five
haplotypes with frequencies of .0.01 were predicted. Ca, cases; Co, controls.
OR, odds ratio relative to all other haplotypes. P-value is from analysis of
effects of all haplotypes on disease risk in a logistic regression model. Odds
ratios and P-values relative to reference haplotype TTT are given in
Supplementary Material, Table S5.
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years; SD+10.8) were the spouses or unrelated friends of
patients with malignancies. None had a personal history of
malignancy at the time of ascertainment. All cases and con-
trols had self-reported European ancestry, and there were no
obvious differences in the demography of cases and controls
in terms of place of residence within the UK.
Scotland2 (SOCCS) comprised 2024 CRC cases (61% male;
mean age at diagnosis 65.8 years, SD+8.4) and 2092 popu-
lation controls (60% males; mean age 67.9 years, SD+9.0)
ascertained in Scotland. Cases were taken from an independ-
ent, prospective, incident CRC case series and aged ,80
years at diagnosis. Control subjects were population controls
matched by age (+5 years), gender and area of residence
within Scotland.
UK3 (NSCCG) comprised 7912 CRC cases (65% male;
mean age at diagnosis 59 years, SD+ 8.2) and 4398 controls
(40% male; mean age 62 years, SD+ 11.5) ascertained
through NSCCG post-2005.
Scotland3 (SOCCS) comprised 1145 CRC cases (50% male;
mean age at diagnosis 53.2 years, SD+15.4) and 2203
cancer-free population controls (47% male; mean age 51.8
years, SD+11.5). Controls were recruited as part of the
Generation Scotland study.
UK4 (CORGI2BCD) consisted of 621 CRC or CRAd cases
(46% male; mean age at diagnosis 58.3 years; SD+14.1) and
1121 cancer-free population or spouse controls (45% male;
mean age 45.1 years, SD+15.9), sampled using the same
criteria as UK1.
Cambridge/SEARCH consisted of 2248 CRC cases (56%
male; mean age at diagnosis 59.2 years, SD+ 8.1) and 2209
controls (42% males; mean age 57.6 years, SD+ 15.1).
Samples were ascertained through the SEARCH (Studies of
Epidemiology and Risk Factors in Cancer Heredity, http://
www.cancerhelp.org.uk/trials/a-study-looking-at-genetic-causes-
of-cancer) study based in Cambridge, UK. Recruitment started
in 2000; initial patient contact was though the general practi-
tioner. Control samples were collected post-2003. Eligible
individuals were sex and frequency matched in 5-year age
bands to cases.
The COIN samples were 2151 cases derived from the
COIN and COIN-B clinical trials of metastatic CRC.
Median age was 63 years. COIN cases were compared
against genotypes from 2501 population controls (1237
males), from the WTCCC2 National Blood Service (NBS)
cohort (50% male; mean age at diagnosis 53.2 years,
SD+15.4).
The Helsinki (FCCPS) study (http://research.med.helsinki.
ﬁ/gsb/aaltonen/) comprised 988 cases from a population-based
collection centred on south-eastern Finland and 864 popula-
tion controls from the same collection.
EPICOLON included 1410 CRC cases matched with the
same number of controls collected in a prospective fashion
from centres in Spain. Exclusion criteria were Mendelian
CRC syndromes and a personal history of inﬂammatory
bowel disease.
The Leiden sample set included 858 unselected cases with
CRC and 690 controls ascertained through genetic testing pro-
grammes for non-cancer-related conditions from the Leiden
area.
In all cases, CRC was deﬁned according to the ninth revi-
sion of the International Classiﬁcation of Diseases (ICD) by
codes 153–154 and all cases had pathologically proven
disease. Only individuals of white European origin were
included in the study.
Sample preparation and genotyping
Collection of blood samples and clinico-pathological informa-
tion from patients and controls was undertaken with informed
consent and ethical review board approval in accordance with
the tenets of the Declaration of Helsinki. DNA was extracted
from samples using conventional methods and quantiﬁed
using PicoGreen (Invitrogen). The VQ, UK1, Scotland1 and
Australia GWA cohorts were genotyped using Illumina
Hap300, Hap370 or Hap550 arrays. 1958BC and NBS geno-
typing was performed as part of the WTCCC2 study on
Hap1.2M arrays. In UK2 and Scotland2, genotyping was con-
ducted using custom Illumina Inﬁnium arrays according to the
manufacturer’s protocols. Some COIN SNPs were typed on
custom Illumina Goldengate arrays. To ensure quality of geno-
typing, a series of duplicate samples was genotyped, resulting
in 99.9% concordant calls in all cases.
Other genotyping was conducted using competitive
allele-speciﬁc PCR KASPar chemistry (KBiosciences Ltd,
Hertfordshire, UK), Taqman (Life Sciences, Carlsbad, CA,
USA) or MassARRAY (Sequenom Inc., San Diego, CA, USA).
All primers, probes and conditions used are available on
request. Genotyping quality control was tested using duplicate
DNA samples within studies and SNP assays, together with
direct sequencing of subsets of samples to conﬁrm genotyping
accuracy.ForallSNPs, .99%concordantresultswereobtained.
We excluded SNPs from analysis if they failed one or more
of the following thresholds: GenCall scores ,0.25; overall
call rates ,95%; minor allele frequency (MAF),0.01;
departure from the Hardy–Weinberg equilibrium (HWE) in
controls at P,10
24 or in cases at P , 10
26; outlying in
terms of signal intensity or X:Y ratio; discordance between
duplicate samples; and, for SNPs with evidence of association,
poor clustering on inspection of X:Y plots. We excluded
individuals from the GWA analyses if they had evidence of
non-white European ancestry by PCA-based analysis in com-
parison with HapMap samples (http://hapmap.ncbi.nlm.nih.
gov/) or by self-report. Deviation of the genotype frequencies
in the controls from those expected under HWE was assessed
by the x
2 test (1 df), or Fisher’s exact test where an expected
cell count was ,5.
Association statistics and imputation
Associations between SNP genotype and disease status were
primarily assessed in STATA v10 (http://www.stata.com/)
and PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/p
link/) using allelic and Cochran–Armitage tests (both with
1df) respectively, or by Fisher’s exact test where an expected
cell count was ,5. Genotypic (2 df), dominant (1 df) and
recessive (1 df) tests were also performed. The risks associated
with each SNP were estimated by allelic, heterozygous and
homozygous ORs using unconditional logistic regression,
and associated 95% CIs were calculated.
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conducted using standard methods for combining raw data
based on the Mantel–Haenszel method in STATA and in
PLINK. Joint ORs and 95% CIs were calculated assuming
ﬁxed- and random-effects models. Tests of the signiﬁcance
of the pooled effect sizes were calculated using a standard
normal distribution. Cochran’s Q statistic to test for heterogen-
eity and the I
2 statistic to quantify the proportion of the total
variation due to heterogeneity were calculated. Large hetero-
geneity is typically deﬁned as I
2≥75%. Where signiﬁcant het-
erogeneity was identiﬁed, results from the random-effects
model were reported. Alongside, we also performed
meta-analysis based on allele dosage (0, 1, 2) and incorporated
age and sex as co-variates. Although age and sex are asso-
ciated with the CRC risk, they were not associated with
SNP genotype and did not materially affect the signiﬁcance
of any of the reported associations (data not shown).
The combined effects of pairs or other multiples of loci
identiﬁed as possibly associated with the CRC risk were
investigated by unconditional or conditional logistic regres-
sion analysis in PLINK and STATA to test for independent
effects of each SNP, stratifying by sample series. Logistic re-
gression was undertaken both pairwise with the original
tagSNP and then in a backwards analysis that initially
included all SNPs with good evidence of association in
each region. We used Haploview software v4.2 (http
://www.broadinstitute.org/haploview) to infer the LD struc-
ture of the genome in the 1q41 and 12q13.13 regions, and
used the expectation maximum algorithms in Haploview or
PLINK to infer haplotypes.
To predict genotypes at untyped SNPs in both regions,
imputation of the UK1, Scotland 1 and VQ58 data sets was
performed using the IMPUTE2 software and the combined
CEU 1000 Genomes low-coverage pilot and complete
HapMap3 haplotypes reference set, which was ﬁltered to
remove duplicate haplotypes (both from https://mathgen.sta
ts.ox.ac.uk/impute/impute_v2.html) (8). Association statistics
for imputed SNPs were calculated in SNPTEST v1.1.5
(www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html)
using the ‘–proper’ option, which is an additive model score
test based on missing data likelihood, to allow for the uncer-
tainty of imputed genotypes (9). Imputed markers with prop-
er_info scores ,0.5, imputed call rates per SNP ,0.9
(using a maximum genotype probability threshold of 0.9 to
call a genotype) and MAFs ,0.01 were excluded from the
analyses. Meta-analyses of the sample sets were carried out
with Meta (10) (http://www.stats.ox.ac.uk/~jsliu/meta.html)
and in STATA, using the genotype probabilities from
IMPUTE2 where a SNP was not directly typed.
The GENECLUSTER program (11) was used to analyse our
UK1, Scotland1 and VQ58 samples speciﬁcally in order to test
whether one- or two-SNP models better ﬁtted the association
signals in each SNP region. GENECLUSTER is a Bayesian
method that uses HapMap haplotypes to estimate genealogy
of samples and by jointly testing all SNPs on each branch of
the genealogy in cases and controls, the program indicates
the identities of the SNP(s) most likely to have the strongest
association signal, thus potentially helping to identify
functional variation. The default model parameters were
used, speciﬁcally mutation model prior: (0.50, 0.50, 0.00),
max number of trees to consider per location: 1 and beta
risk prior parameters: (5.00, 5.00).
Essentially for comparative purposes, we also ran the Mar-
garita program (12), based on ancestral recombination graphs
(ARGs), in UK1, Scotland1 and VQ58 for the genotyped SNPs
in the 1q and 12q regions. This program aims to maximize
available information as to the location and identity of a func-
tional SNP by reconstructing the genealogical history of the
sample population. For each ARG, a putative risk mutation
is placed on the marginal tree and the frequency of each
branch in cases and controls is assessed. For each region,
30ARGs were constructed and the signiﬁcance of a SNP at
each branchpoint assessed by 10 000 permutations. Unlike
GENECLUSTER, Margarita does not speciﬁcally address
the issue of whether there are two independent underlying
SNP in each region, and comparison was therefore restricted
to the single-SNP scenario.
Genome co-ordinates were taken from the NCBI build
36/hg18 (dbSNP b126).
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Supplementary Material is available at HMG online.
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